irinotecan has been researched along with Epithelial Neoplasms in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arakawa, A; Itani, Y; Ito, K; Kawaguchi, R; Shiozaki, T; Tabata, T; Takeuchi, S; Toyoda, S; Tsubamoto, H | 1 |
| Fujimori, K; Kaido, Y; Kaiho, M; Mizunuma, H; Nishiyama, H; Omi, H; Otsuki, T; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Yaegashi, N; Yokoyama, Y | 1 |
| Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Bai, H; Liu, Y; Ma, N; Ren, Z; Wang, F; Xu, S | 1 |
| Ding, YY; Song, LX; Xu, JF; Xu, Q | 1 |
| Fukagawa, S; Katsuda, T; Kondo, H; Maehara, M; Miyahara, D; Miyamoto, S; Miyata, K; Nam, SO; Ueda, T | 1 |
| Cardillo, TM; Goldenberg, DM; Govindan, SV; Sharkey, RM; Trisal, P | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Aoki, D; Chiyoda, T; Kataoka, F; Nomura, H; Susumu, N; Tominaga, E; Tsuda, H; Yamagami, W | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Gershenson, DM | 1 |
| Bodurka, DC; Gano, J; Gershenson, DM; Kavanagh, JJ; Levenback, C; Wharton, JT; Wolf, JK | 1 |
| Akbulut, H; Deisseroth, A; Maynard, J; Pizzorno, G; Tang, Y; Zhang, L | 1 |
| Furman, WL; Hanna, SK; Houghton, PJ; Ma, MK; Radomski, KM; Santana, VM; Smith, AK; Stewart, CF; Zamboni, WC | 1 |
1 review(s) available for irinotecan and Epithelial Neoplasms
| Article | Year |
|---|---|
Irinotecan in epithelial ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Irinotecan; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Topoisomerase I Inhibitors | 2002 |
6 trial(s) available for irinotecan and Epithelial Neoplasms
| Article | Year |
|---|---|
Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2013 |
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols | 2014 |
Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Survival Rate; Taxoids; Treatment Outcome | 2015 |
The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Treatment Outcome | 2015 |
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Camptothecin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunoenzyme Techniques; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms | 2003 |
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Complex and Mixed; Neoplasms, Connective and Soft Tissue; Neoplasms, Glandular and Epithelial; Neutropenia; Time Factors | 2000 |
8 other study(ies) available for irinotecan and Epithelial Neoplasms
| Article | Year |
|---|---|
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Cisplatin; Diarrhea; DNA-Binding Proteins; Endonucleases; Female; Gene Expression; Gene Frequency; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polymorphism, Genetic; Treatment Outcome | 2015 |
Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Immunoconjugates; Immunoglobulin G; Irinotecan; Macaca fascicularis; Male; Mice; Mice, Nude; Models, Biological; Monkey Diseases; Neoplasms, Glandular and Epithelial; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Mucositis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy | 2012 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Combined Modality Therapy; Cytosine Deaminase; Disease Models, Animal; Drug Delivery Systems; Female; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasms, Glandular and Epithelial; Promoter Regions, Genetic; Ribosomes; RNA, Messenger; Thymidylate Synthase; Time Factors; Transcription, Genetic | 2004 |